S
Said Jongo
Researcher at Ifakara Health Institute
Publications - 25
Citations - 813
Said Jongo is an academic researcher from Ifakara Health Institute. The author has contributed to research in topics: Plasmodium falciparum & PfSPZ vaccine. The author has an hindex of 10, co-authored 19 publications receiving 514 citations.
Papers
More filters
Journal ArticleDOI
A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein
Joshua Tan,Joshua Tan,Brandon K. Sack,David Oyen,Isabelle Zenklusen,Isabelle Zenklusen,Luca Piccoli,Sonia Barbieri,Mathilde Foglierini,Mathilde Foglierini,Chiara Silacci Fregni,Jessica Marcandalli,Said Jongo,Salim Abdulla,Laurent Perez,Giampietro Corradin,Luca Varani,Federica Sallusto,Federica Sallusto,Betty Kim Lee Sim,Stephen L. Hoffman,Stefan H. I. Kappe,Claudia Daubenberger,Claudia Daubenberger,Ian A. Wilson,Antonio Lanzavecchia,Antonio Lanzavecchia +26 more
TL;DR: This study isolated IgM and IgG monoclonal antibodies from Tanzanian volunteers who were immunized with repeated injection of Sanaria PfSPZ Vaccine and who were found to be protected from controlled human malaria infection with infectious homologous PfSPzs.
Journal ArticleDOI
Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults.
Said Jongo,Seif Shekalaghe,L. W. Preston Church,Adam Ruben,Tobias Schindler,Tobias Schindler,Isabelle Zenklusen,Isabelle Zenklusen,Tobias Rutishauser,Tobias Rutishauser,Julian Rothen,Julian Rothen,Anneth Tumbo,Catherine Mkindi,Maximillian Mpina,Ali Mtoro,Andrew S. Ishizuka,Kamaka R Kassim,Florence A. Milando,Munira Qassim,Omar Juma,Solomon Mwakasungula,Beatus Simon,Eric R. James,Yonas Abebe,Natasha Kc,Sumana Chakravarty,Elizabeth Saverino,Bakari M Bakari,Peter F. Billingsley,Robert A. Seder,Claudia Daubenberger,Claudia Daubenberger,B. Kim Lee Sim,Thomas L. Richie,Marcel Tanner,Marcel Tanner,Salim Abdulla,Stephen L. Hoffman +38 more
TL;DR: The same dosage regimen was used in the United States and Mali to evaluate the tolerability, safety, immunogenicity, and VE of PfSPZ Vaccine in young adult male Tanzanians and found it was less immunogenic and protective in Tanzanian volunteers than in Americans.
Journal ArticleDOI
Public antibodies to malaria antigens generated by two LAIR1 insertion modalities
Kathrin Pieper,Joshua Tan,Joshua Tan,Luca Piccoli,Mathilde Foglierini,Mathilde Foglierini,Sonia Barbieri,Yiwei Chen,Yiwei Chen,Chiara Silacci-Fregni,Tobias Wolf,Tobias Wolf,David Jarrossay,Marica Anderle,Abdirahman I. Abdi,Francis M. Ndungu,Ogobara K. Doumbo,Boubacar Traore,Tuan M. Tran,Said Jongo,Isabelle Zenklusen,Peter D. Crompton,Claudia Daubenberger,Claudia Daubenberger,Peter C. Bull,Federica Sallusto,Federica Sallusto,Antonio Lanzavecchia,Antonio Lanzavecchia +28 more
TL;DR: In this article, the extracellular domain of LAIR1, a collagen-binding inhibitory receptor encoded on chromosome 19 (ref. 1), was inserted between the V and DJ segments of an antibody.
Journal ArticleDOI
The adjuvant GLA-SE promotes human Tfh cell expansion and emergence of public TCRβ clonotypes
Danika L. Hill,Wim Pierson,Daniel J. Bolland,Catherine Mkindi,Edward J. Carr,Edward J. Carr,Jiong Wang,Sophie Houard,Steven W. Wingett,Régine Audran,Elizabeth F. Wallin,Said Jongo,Kassim Kamaka,Martin S. Zand,François Spertini,Claudia Daubenberger,Claudia Daubenberger,Anne E. Corcoran,Michelle A. Linterman +18 more
TL;DR: This work shows the adjuvant GLA-SE enhances circulating Tfh cells and enduring antibody responses to a malaria vaccine in Tanzanian adults.
Public antibodies to malaria antigens generated by two LAIR1 insertion modalities
Kathrin Pieper,Joshua Tan,Luca Piccoli,Mathilde Foglierini,Sonia Barbieri,Yiwei Chen,Chiara Silacci-Fregn,Tobias Wolf,David Jarrossay,Marica Anderle,Abdirahman I. Abdi,Francis M. Ndungu,Ogobara K. Doumbo,Boubacar Traore,Tuan M. Tran,Said Jongo,Isabelle Zenklusen,Peter D. Crompton,Claudia Daubenberger,Peter C. Bull,Federica Sallusto,Antonio Lanzavecchia +21 more
TL;DR: It is reported that 5–10% of malaria-exposed individuals, but none of the European blood donors tested, have high levels of LAIR1-containing antibodies that dominate the response to infected erythrocytes without conferring enhanced protection against febrile malaria.